Fig. 5
Swimmer plots of patients. Patients who received anlotinib plus oxaliplatin and capecitabine as first-line therapy in RAS/BRAF wild-type unresectable mCRC
Fig. 5 | BMC Medicine
Swimmer plots of patients. Patients who received anlotinib plus oxaliplatin and capecitabine as first-line therapy in RAS/BRAF wild-type unresectable mCRC